

Identification of antigen-specific TCR sequences based on biological and statistical enrichment in unselected subjects

Neal P. Smith, ... , J. Christopher Love, Wayne G. Shreffler

JCI Insight. 2021. <https://doi.org/10.1172/jci.insight.140028>.

Resource and Technical Advance In-Press Preview Immunology

Recent advances in high-throughput T cell receptor (TCR) sequencing have allowed for new insights into the human TCR repertoire. However, methods for capturing antigen-specific repertoires remain an area of development. Here, we describe a potentially novel approach that utilizes both a biological and statistical enrichment to define putatively antigen-specific complementarity-determining region 3 (CDR3) repertoires in unselected individuals. The biological enrichment entails fluorescence-activated cell sorting of in vitro antigen-activated memory CD4+ T cells, followed by TCR β sequencing. The resulting TCR β sequences are then filtered by selecting those that are statistically enriched when compared to their frequency in the autologous resting T cell compartment. Applying this method to define putatively peanut protein-specific repertoires in 27 peanut-allergic individuals resulted in a library of 7345 unique CDR3 β amino acid sequences that had similar characteristics to other validated antigen-specific repertoires in terms of homology and diversity. In-depth analysis of these CDR3 β s revealed 36 public sequences that demonstrated high levels of convergent recombination. In a network analysis, the public CDR3 β s unveiled themselves as core sequences with more edges than their private counterparts. This method has the potential to be applied to a wide range of T cell-mediated disorders, and to yield new biomarkers and biological insights.

Find the latest version:

<https://jci.me/140028/pdf>



1 **Title**
2 Identification of antigen-specific TCR sequences based on biological and statistical enrichment
3 in unselected subjects
4

5 **Authors**
6 Neal P. Smith^{1*}, Bert Ruiters^{1,2*}, Yamini V. Virkud^{1, 2, 3}, Ang A. Tu⁴, Brinda Monian⁴, James J.
7 Moon^{1, 2, 5}, J. Christopher Love⁴, Wayne G. Shreffler^{1, 2, 3}
8

9 **Affiliations**
10 ¹ Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston,
11 MA.
12 ² Harvard Medical School, Boston, MA.
13 ³ Food Allergy Center, Massachusetts General Hospital, Boston, MA.
14 ⁴ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology,
15 Cambridge, MA.
16 ⁵ Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston,
17 MA

18 *These authors contributed equally to this work
19

20 **Corresponding author:**
21 Neal P. Smith
22 Massachusetts General Hospital
23 Center for Immunology & Inflammatory Diseases
24 Room 8.215
25 149 13th Street
26 Boston, MA 02129
27 nsmith19@mgh.harvard.edu
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Conflict of interest statement**

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

JCL has interests in Sunflower Therapeutics PBC, Pfizer, Honeycomb Biotechnologies, OneCyte Biotechnologies, SQZ Biotechnologies, Alloy Therapeutics, QuantumCyte, Amgen, and Repligen. JCL’s interests are reviewed and managed under Massachusetts Institute of Technology’s (MIT’s) policies for potential conflicts of interest. JCL receives sponsored research support at MIT from Amgen, the Bill & Melinda Gates Foundation, Biogen, Pfizer, Roche, Takeda, and Sanofi. The spouse of JCL is an employee of Sunflower Therapeutics PBC.

WGS has interests in Aimmune Therapeutics, Allergy Therapeutics, FARE, DBV Biotechnologies, Merck, and Sanofi. WGS’s interests are reviewed and managed under Mass General Brigham’s policies for potential conflicts of interest. WGS receives sponsored research support at MGH from Aimmune, DBV, The Demarest Lloyd Foundation, The Food Allergy Science Initiative at the Broad Institute, Regeneron, and Vedanta.

93 **Abstract**

94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120

Recent advances in high-throughput T cell receptor (TCR) sequencing have allowed for new insights into the human TCR repertoire. However, methods for capturing antigen-specific repertoires remain an area of development. Here, we describe a potentially novel approach that utilizes both a biological and statistical enrichment to define putatively antigen-specific complementarity-determining region 3 (CDR3) repertoires in unselected individuals. The biological enrichment entails fluorescence-activated cell sorting of *in vitro* antigen-activated memory CD4⁺ T cells, followed by TCR β sequencing. The resulting TCR β sequences are then filtered by selecting those that are statistically enriched when compared to their frequency in the autologous resting T cell compartment. Applying this method to define putatively peanut protein-specific repertoires in 27 peanut-allergic individuals resulted in a library of 7345 unique CDR3 β amino acid sequences that had similar characteristics to other validated antigen-specific repertoires in terms of homology and diversity. In-depth analysis of these CDR3 β s revealed 36 public sequences that demonstrated high levels of convergent recombination. In a network analysis, the public CDR3 β s unveiled themselves as core sequences with more edges than their private counterparts. This method has the potential to be applied to a wide range of T cell-mediated disorders, and to yield new biomarkers and biological insights.

121 **Introduction**

122 T cells are defined by their antigen-specific T cell receptor (TCR), and the collection of
123 all TCRs in a human, which is dynamic and comprises approximately 10^{10} unique TCRs at a
124 given time, is known as their TCR repertoire (1). TCRs are dimeric proteins comprising of an α
125 and β chain that are both generated through the process of genomic rearrangement of germline V
126 (Variable), D (Diversity) and J (Joining) genes concurrent with random nucleotide insertions and
127 deletions in the VDJ junction. This junction, known as the CDR3 (complementarity-determining
128 region 3), interacts most closely with an epitope during antigen presentation, and is therefore the
129 primary focus of studies aiming to elucidate the mechanisms of TCR specificity (2).

130 To date, *ex vivo* analysis of antigen-specific TCRs has largely used selection of T cells by
131 peptide-MHC (pMHC)-multimer (e.g. tetramer) binding and fluorescence-activated cell sorting
132 (FACS). Of the 78,701 listed antigen-specific TCRs in the VDJdb (vdjdb.cdr3.net), 73,964
133 (94%) were reported to be isolated via pMHC-multimer selection (3). In addition, new
134 methodologies aimed at defining features that confer antigen-specificity have been benchmarked
135 on various anti-viral TCRs selected by pMHC-tetramers (2, 4). The advantage of tetramer
136 selection is the inherent functional validity it provides, as it labels cells specific for a single well-
137 defined epitope. However, it comes with a major drawback in the form of a limited scope of
138 analysis. Most immune responses are poly-antigenic, and current T cell epitope mapping
139 information of most antigens is incomplete. Additionally, pMHC-tetramers can only be used
140 with T cell donors that have genetically matched HLA alleles. Thus, tetramer-selection with
141 only known epitopes in specific genetic backgrounds will likely provide an incomplete
142 understanding of the antigen-specific TCR repertoire and T cell-mediated immune responses.

143 Public TCRs defined on the basis of identical amino acid sequences across multiple
144 individuals have been described in many contexts since the early 1990s. Their existence has been
145 intriguing given the vast number of possible recombination events, which suggests the
146 prevalence of public TCRs would be much lower than what has been observed (5, 6). One major
147 mechanism that shapes an antigen-specific public TCR repertoire is convergent recombination.
148 Herein, selective pressure such as that seen in response to dominant antigenic epitopes across
149 individuals, gives rise to the presence of multiple unique nucleotide sequences producing the
150 same ‘public’ amino acid CDR3, due to genetic code degeneracy and homologous gene segments
151 (7). Defining the public TCR repertoire for antigen-specific responses can help in the
152 development of diagnostics and therapeutics in T cell driven disorders.

153 Peanut allergy is a rising public health concern, and currently affects more than 1% of the
154 US population. Compared with other food allergies, peanut allergy is less frequently outgrown
155 and more often presents with severe symptoms (8). Reactions to allergens are mediated by
156 activation of mast cells and basophils through the high-affinity IgE receptor, occurring when
157 receptor-bound specific IgE is cross-linked by binding to peanut allergens. Production of this
158 high affinity allergen-specific IgE is T cell-dependent, and a peanut-specific transcriptional
159 profile characterized by increased expression of *IL4*, *IL5*, *IL9* and *IL13* has been observed in
160 CD4⁺ T cell subsets from subjects with peanut allergy (9-11). Multiple forms of immunotherapy
161 for the treatment of peanut allergy are currently in clinical trials, of which oral immunotherapy is
162 the most common. The effects of these treatments on the peanut-specific CD4⁺ T cell response
163 and their correlation with clinical success are an active area of investigation(12, 13).

164 In this work, we investigated the antigen-specific TCR repertoires of peanut-allergic
165 individuals. We isolated peanut protein-activated and resting memory CD4⁺ T cells and

166 sequenced the CDR3 of the TCR β -chain (CDR3 β). The most enriched sequences in the peanut-
167 activated compartment were identified as putatively peanut-specific CDR3 β s (ps-CDR3s).
168 These biologically and statistically enriched sequences exhibited properties associated with
169 antigen-specific populations, such as increased homology, decreased diversity, and instances of
170 convergent recombination. Within our pool of ps-CDR3s, we found a subset of sequences
171 enriched in multiple subjects (i.e. public ps-CDR3s), suggesting the existence of public T cell
172 responses among peanut-allergic individuals with diverse HLA genotypes. This work describes a
173 potentially novel method to study antigen-specific TCR repertoires without restriction to known
174 T cell epitopes or the availability of matched MHC reagents. This method is potentially
175 applicable to studies of various T cell-mediated diseases beyond the scope of allergy.

176

177

178

179

180

181

182

183

184

185

186

187

188

189 **Results**

190 *Selection of putatively peanut-specific CDR3 β sequences*

191 With the goal of enriching for antigen-specific memory CD4⁺ T cells, peripheral blood
192 mononuclear cells (PBMCs) from 27 peanut-allergic individuals were cultured for 20 hours with
193 a peanut protein extract. Demographic and serological data for the subjects in this study can be
194 found in Table 1. The activation marker CD154 (CD40L) was used to discriminate between
195 peanut-activated (CD154⁺) and resting (CD154⁻CD69⁻) memory T cells, and TCR CDR3 β
196 sequences were generated from both populations (Fig. 1A, Suppl. Fig. 1, Suppl. Table 1) (10,
197 14). Flow-cytometric analysis revealed that stimulation with peanut protein increased the
198 frequency of CD154-expressing CD4⁺ memory T cells as compared to unstimulated cultures
199 (median[IQR] CD154⁺ cells per million CD4⁺ T cells: 2504[1328, 4105] stimulated vs. 172[117,
200 319] unstimulated; $P < 0.0001$) (Fig. 1B). To filter out sequences that were likely to be present
201 in the CD154⁺ population due to bystander activation, we developed a statistical enrichment
202 strategy to define putatively peanut-specific CDR3 β sequences (ps-CDR3s). First, a *G*-test of
203 independence was applied to all CDR3 β sequences in the peanut-activated compartment and
204 adjusted P-values (q-values) were generated based on a FDR of $q < 0.05$. Sequences were
205 further filtered to include only those with read counts ≥ 2 in the activated compartment, and
206 those with a higher proportion in the activated compartment than in the resting compartment.
207 This approach defined 7345 out of the 53205 unique amino acid sequences in the peanut-
208 activated compartment (14%) across our 27 peanut-allergic individuals as ps-CDR3s, which met
209 all three selection criteria. While the vast majority ($n = 7309$) of ps-CDR3s were private, 36
210 unique amino acid sequences (0.49% of ps-CDR3s) were significantly enriched in more than one
211 individual (i.e., public). Of these public sequences, 33 were found in only two individuals.

212 However, one ps-CDR3 (CASSFRFLSGRALNEQFF) was statistically enriched in 8 of the 27
213 subjects, suggesting strong selective pressure for entrance of this sequence into the peanut-
214 specific memory T cell repertoire (Suppl. Fig. 2). The CDR3 β amino acid and nucleotide
215 sequences that met our ps-CDR3 enrichment criteria only represented a minor fraction of the
216 entire CDR3 β pool from peanut-activated T cells (amino acid: median 14.1%, nucleotide:
217 median 14.5%), indicating a high level of stringency with this statistical approach. The median
218 frequency of ps-CDR3s was 117 per million CD4⁺ T cells (IQR = 46.8, 173.15), which
219 corresponds well to published frequencies of whole allergen-specific T cells in allergic
220 individuals, suggesting the level of stringency is appropriate (Fig. 1C) (11, 15, 16).

221 We compared this strategy for TCR enrichment to the established approach of selecting
222 antigen-specific TCRs by pMHC-tetramer binding. PBMCs from one of the 27 subjects were
223 cultured with the major peanut allergen Ara h 1 for 20 hours to isolate CD154⁺ and CD154⁻ T
224 cells by FACS, or for 2 weeks to expand the Ara h 1-specific T cell population and isolate Ara h
225 1 (AA 415-426) tetramer⁺ and tetramer⁻ T cells (Suppl. Fig. 3A). TCR CDR3 β sequences were
226 generated, and our method of statistical enrichment was applied to both populations, comparing
227 CD154⁺ to CD154⁻ CDR3 β s and tetramer⁺ to tetramer⁻ CDR3 β s respectively, to filter out
228 bystander-activated clones or those present due to non-specific binding of tetramer. We selected
229 458 ps-CDR3s from the CD154⁺ population (accounting for 34.1% of total CD154⁺ reads, and
230 17.9% of unique CD154⁺ CDR3 β s) and 175 ps-CDR3s from the tetramer⁺ population (82.2% of
231 total tetramer⁺ reads, 17.3% of unique tetramer⁺ CDR3 β s), and detected 11 clones that were
232 present in both populations (Suppl. Fig. 3B). Interestingly, these 11 ps-CDR3s were among the
233 most expanded clones in the tetramer⁺ population, indicating that our approach captures the most
234 dominant peanut-specific TCRs (Suppl. Fig. 3C). Moreover, the relatively low frequency of

235 tetramer⁺ clones present in the CD154⁺ population (11 out of 458, or 2.4%) highlights the
236 capacity of this strategy to identify ps-CDR3s beyond those specific for the single epitope used
237 in the pMHC-tetramer.

238

239 *ps-CDR3s are more similar and less diverse than unselected CDR3βs from both activated and*
240 *resting T cells*

241 To assess the efficacy of our statistical enrichment method for selecting those sequences
242 most likely to be peanut-specific, we examined the similarity of the ps-CDR3s using Hamming
243 and Levenshtein distances. For each ps-CDR3, the minimum Hamming and Levenshtein
244 distances were measured by determining the minimum number of amino acid differences
245 compared to its next closest ps-CDR3. As a control, the minimum Hamming and Levenshtein
246 distances of equal-sized random repeated samplings of resting (CD154⁻) and activated (CD154⁺)
247 CDR3βs were also measured (Fig. 2A, B). There were significantly more sequences with a
248 minimum Hamming distance of 0-2 and Levenshtein distance of 0-1 in the ps-CDR3s than in
249 either the activated or resting CDR3βs ($P < 0.01$), indicating enhanced similarity among the
250 statistically enriched sequences. Importantly, these metrics showed no differences between
251 unselected activated vs. resting CDR3βs, supporting our hypothesis that there is a substantial
252 number of non-peanut-specific sequences in the CD154⁺ population, and that our statistical
253 enrichment strategy is effective in removing them.

254 We performed uniform resampling of autologous sets of ps-CDR3s, activated and resting
255 CDR3β sequences to measure Hill's diversity index across different diversity orders to capture
256 both the true richness (low q value) and abundance (high q value) of the samples (Fig. 2C) (17).
257 For the 25 subjects with > 30 ps-CDR3s, the general diversity index was significantly lower for

258 the ps-CDR3s than for either the activated or resting sequences at diversity orders 0-2 ($P < 0.01$).
259 Consistent with biological enrichment, the diversity of the activated sequences was significantly
260 lower than that of the resting samples at diversity orders 0-2 for 22 of the 25 subjects ($P < 0.01$).
261 Furthermore, the difference in diversity between the ps-CDR3s and either the activated or resting
262 CDR3 β s was significantly greater than the difference observed between the activated and resting
263 CDR3 β s ($P < 0.001$), emphasizing the utility in our statistical filtering (Fig. 2D).

264

265 *Public ps-CDR3s are closer to germline and show evidence of convergent recombination*

266 Antigen-specific public TCRs from individuals with different HLA genotypes can
267 provide valuable insights into shared immune responses within a diverse population. For this
268 reason, we wanted to further examine the characteristics of our public ps-CDR3s. We observed
269 that the public ps-CDR3s contained fewer total N-nucleotide insertions than the private ps-
270 CDR3s (median public: 3 insertions, median private: 7 insertions; $P < 0.01$). Similar patterns
271 were observed when looking specifically at V-D insertions (median public: 1 insertion, median
272 private: 3 insertions; $P < 0.01$) and D-J insertions (median public: 1 insertion, median private: 3
273 insertions; $P < 0.01$), which is consistent with prior literature demonstrating that public TCRs are
274 closer to germline (Fig. 3A) (7, 18-20).

275 Convergent recombination of TCRs (i.e. multiple TCR nucleotide sequences translating
276 to the same amino acid sequence) is a characteristic of antigenic selection (7). We searched the
277 ps-CDR3s for this phenomenon and observed that convergence occurred in 467 out of 7345
278 unique ps-CDR3 amino acid sequences (6.4%). Interestingly, convergence was very common
279 among the public ps-CDR3s, occurring in 33 out of 36 public amino acid sequences (91.7%),
280 which suggests a strong selective pressure for these sequences' entrance into the peanut-specific

281 memory T cell pool. Additionally, the number of nucleotide sequences encoding each public ps-
282 CDR3 was significantly higher than the number for each private ps-CDR3 (median public: 2
283 sequences, median private: 1 sequence; $P < 0.001$) (Fig. 3B). Analysis of the 3 most convergent
284 public ps-CDR3s (≥ 5 unique nucleotide sequences) demonstrated convergence derived from
285 germline (V-gene) and non-germline (N-nucleotide insertions) changes (Fig. 3C).

286 To obtain full TCR sequences of the public ps-CDR3s, PBMCs from 12 of the 27 peanut-
287 allergic subjects from the initial analysis were stimulated with peanut protein extract for 20 hours
288 and single-cell TCR α and TCR β capture and sequencing was performed by Seq-Well on FACS-
289 sorted peanut-activated CD154⁺ memory T cells (21). Of the 36 public ps-CDR3 TCR β
290 sequences, 15 were found in at least 1 cell (41.7%), with 10 having matched TCR α and TCR β
291 sequences (27.8%) (Table 2).

292

293 *Analysis of ps-CDR3 amino acid sequences reveals public, dominant motifs*

294 Given the ps-CDR3 sequences demonstrated enhanced overall similarity, a motif analysis
295 was performed according to Glanville et al. (2), to find dominant patterns among the putatively
296 peanut-specific pool of sequences (Suppl. Fig. 4A). Briefly, for all ps-CDR3s, the region most
297 likely to be in contact with an antigenic peptide was broken into continuous 3mer, 4mer and
298 5mer amino acid sequences. In addition, discontinuous 4mers and 5mers were generated to
299 allow for the detection of motifs with gaps. Nmers that were at least 10-fold enriched in the ps-
300 CDR3s as compared to the resting sequences and found in at least 3 unique ps-CDR3s from at
301 least 3 individuals, were considered dominant motifs (Fig. 4A-B, Suppl. Fig. 4B-D). These
302 criteria were met by 148 of the 104520 unique nmer sequences (0.14%), and the proportion of
303 dominant motifs in the total motif pool was fairly similar for each nmer size (0.06 - 0.16%)

304 (Table 3). With these strict criteria, 399 of the 7345 ps-CDR3s (5.4%) contained at least one
305 dominant motif. These motifs likely represent sequences specific for the most immunogenic T
306 cell epitopes in peanut protein. Indeed, there were significantly more public ps-CDR3s (16.6%)
307 than private ps-CDR3s (5.3%) that contained a dominant motif, supporting the hypothesis that
308 these motifs are associated with the most common epitopes ($P < 0.05$) (Fig. 4C).

309

310 *Network analysis confirms that public ps-CDR3s are core sequences*

311 Utilizing the measured metrics of similarity, the dominant motifs and evidence of
312 convergent recombination, we performed a network analysis to group highly homologous
313 sequences (Fig. 5A). Similar to previously published approaches (2, 22, 23), each ps-CDR3
314 amino acid sequence was treated as a node and an edge was created between nodes if the ps-
315 CDR3s were within a Levenshtein distance of 1 or shared a dominant motif. In addition, self-
316 edges were created to represent additional nucleotide sequences for a corresponding amino acid
317 sequence. Overall, there were 1759 edges created among 1324 ps-CDR3s. Interestingly, the
318 majority ($n = 23$; 63.9%) of public ps-CDR3s were present in the network, whereas a much
319 smaller fraction of private ps-CDR3s ($n = 1301$; 17.7%) were found in the graph ($P < 0.001$)
320 (Fig. 5B). Moreover, the node degree (the number of edges per node) of the public sequences
321 was higher than that of the private sequences (public median node degree: 4, private median
322 node degree: 2; $P < 0.001$) (Fig. 5C). To assess the amount of structure observed among the ps-
323 CDR3s, we compared the number of edges in the ps-CDR3 graph to the median number of edges
324 created when performing the same network analysis on equal-sized random repeated samplings
325 of activated or resting CDR3 β s. Indeed, there were significantly more edges created between the
326 ps-CDR3s than between all activated (CD154⁺) CDR3 β s (median 1234 edges) or resting

327 (CD154⁻) CDR3 β s (median 1091 edges) ($P < 0.001$) (Fig. 5D). We hypothesized that specific
328 clusters of CDR3 β s would be associated with individual HLA genotypes, which are shown in
329 Suppl. Table 2, but no correlations could be found. Taken together, these data suggest that
330 public ps-CDR3s represent “core” sequences that likely bind dominant T cell epitopes in peanut
331 protein, which are recognized by multiple peanut-allergic individuals.

332

333 *The frequency of ps-CDR3s is highest in the T_H17 subset, but the clonal expansion of ps-CDR3s*
334 *is highest in the T_H2 subset*

335 To better understand the phenotypes of the CD4⁺ T cells from which ps-CDR3s were
336 derived, TCR β sequencing was performed on bulk T_H1 (CXCR3⁺CCR5⁺), T_H2
337 (CRTH2⁺CCR4⁺), T_H17 (CD161⁺CCR6⁺) and T_{FH} (CXCR5⁺) cells from 8 of the 27 subjects
338 used in the initial analysis (Suppl. Fig. 5, Suppl. Table 1). These bulk TCR β sequences were
339 then probed for ps-CDR3 amino acid sequences derived from the corresponding subjects, and the
340 proportion of ps-CDR3 reads was observed to be highest in the T_H17 subset (Fig. 6A). However,
341 ps-CDR3s detected in the T_H2 subset showed a higher level of clonal expansion than ps-CDR3s
342 in the other subsets, indicating that the most dominant peanut-specific T cell clones have a T_H2
343 phenotype ($P < 0.01$) (Fig. 6B). Although ps-CDR3s were predominantly detected within a
344 single T cell subset, we also observed shared sequences across the subsets, and these were more
345 common among the public ps-CDR3s than private ps-CDR3s. In addition, shared sequences were
346 most often found between the T_H1 and T_H17 phenotypes (Fig. 6C). These data suggest either
347 shared epitope recognition by T cells from these subsets, or plasticity between T_H1 and T_H17 cell
348 states, supporting recently published data on colonic T helper subsets in the gut (24).

349

350 Discussion

351 Selection of antigen-specific T cells based on their ability to bind an MHC-peptide
352 complex (pMHC-multimer selection) is a widely used technique. This method, however,
353 depends on a priori knowledge of T cell epitopes in subjects with specific HLA backgrounds,
354 and is therefore limited in scope. Here, we expand upon a method not constrained by these
355 limitations, utilizing a biological enrichment and augmenting it with a statistical enrichment to
356 isolate likely antigen-specific CDR3 β s that are not derived from bystander-activated T cells.
357 This approach generated a library of ps-CDR3s that exhibited properties of an antigen-specific
358 pool in terms of diversity, homology and convergence. Using these features in a network
359 analysis to cluster similar sequences, we were able to show that public ps-CDR3s tended to have
360 more neighbors (i.e. were more similar) than private ps-CDR3s, which corresponds with
361 observations made by Madi et al. (23). When using the ps-CDR3s to probe the T_H-cell subset
362 repertoires from a selection of the peanut-allergic individuals, we found that ps-CDR3s were
363 most frequently present within the T_H17 subset, but those ps-CDR3s within the T_H2 subset were
364 most clonally expanded. These data substantiate previous observations from our group, as we
365 found that peanut-activated memory CD4⁺ T cells from peanut-allergic patients highly express
366 both T_H17- and T_H2-related genes. However, only T_H2-related gene expression and cytokine
367 production distinguished patients with high clinical sensitivity to peanut from those with low
368 sensitivity (10).

369 The use of CD154 as a marker to isolate antigen-activated T cells was first described in
370 2005, when Frensch et al. demonstrated the utility of this method with an array of microbial and
371 allergenic antigens (25). Since then, numerous other groups have successfully applied this
372 method with allergens and pathogen-derived proteins to better describe the phenotypes of

373 antigen-specific CD4⁺ T cell populations (11, 14, 26-29). However, utilizing this methodology
374 to better characterize antigen-specific TCR repertoires is in its infancy. Glanville et al. single-
375 cell sorted and sequenced the TCRs of CD154⁺ T cells activated with an *M. tuberculosis* lysate
376 and successfully validated antigen-specific motifs with an *in vitro* binding assay, demonstrating
377 that CD154 up-regulation is a valid method to study antigen-specific repertoires (2). Given the
378 concern of bystander activation of non-antigen-specific T cells, we chose to use the CD154 up-
379 regulation assay in conjunction with a statistical enrichment approach to define our library of ps-
380 CDR3s. This statistical enrichment has the distinct advantage of utilizing autologous resting
381 memory TCR repertoires as a reference when selecting the ps-CDR3s, therefore controlling for
382 the presence of clones in the CD154⁺ compartment due to bystander activation of common
383 clones. The ps-CDR3s exhibited characteristics associated with antigen-specific TCR pools,
384 such as increased similarity and decreased diversity, when compared to both resting as well as
385 total activated CDR3 β s. These findings emphasize the utility of applying the biological (CD154
386 up-regulation) and statistical (*G*-test of independence) enrichments in combination when
387 determining the most relevant TCRs.

388 The application of this method for defining antigen-specific ps-CDR3s has the potential
389 to answer a wide array of biological questions. As described here, antigen-specific ps-CDR3
390 libraries can be used to probe phenotypically defined subsets of CD4⁺ T cells to better
391 understand the phenotype and physiology of antigen-specific T cells. Recently, our group has
392 successfully used a similar approach to identify differences in the peanut-specific CD4⁺ T cell
393 repertoire and phenotypes between peanut-allergic individuals with high and low clinical
394 sensitivity (10). We found that high clinical sensitivity correlates with an expanded and more
395 diverse peanut-specific effector T cell population. Our strategy could also be extended to track

396 antigen-specific ps-CDR3s across a time-course or therapy. Examining the clones that expand or
397 contract in response to an intervention could lead to insights regarding efficacy or susceptibility
398 to side-effects.

399 A major advantage of our approach is that it is unbiased in terms of MHC restriction,
400 representing the complete CD4⁺ T cell response to one or multiple antigenic proteins, which is
401 unlikely to be captured with pMHC-multimer-based sorting. In a previous study, Ryan et al. used
402 a pMHC-dextramer approach to select Ara h 2-specific T cells from peanut-allergic individuals
403 with a defined HLA background (*HLA-DRB1*1501*, *HLA-DRB4*) (12). While this method was
404 successful in identifying phenotypic changes in Ara h 2-specific T cells over the course of peanut
405 oral immunotherapy, the authors were only able to define 13 Ara h 2-specific TCRs, providing
406 limited insights into the peanut-specific repertoire. Of note, we did not find any of the 13
407 reported Ara h 2-specific TCRs within our ps-CDR3s. In the present study, we observed that the
408 most expanded CDR3 β sequences captured by using an Ara h 1 (AA 415-426) pMHC-tetramer
409 were also present among ps-CDR3s from Ara h 1-activated CD154⁺ T cells of the same patient
410 (Suppl. Fig. 3). These data indicate that our approach based on biological and statistical
411 enrichment detects the most relevant CDR3 β s specific for known T cell epitopes. Furthermore,
412 the ps-CDR3s from Ara h 1-activated T cells included hundreds of additional antigen-enriched
413 sequences, suggesting our epitope-agnostic approach is capturing more of the antigen-specific
414 repertoire.

415 Using a method agnostic to both HLA genotype and known epitopes can help to better
416 define the TCR landscape of a given immune response. For example, our study enabled us to
417 describe the public nature of 36 unique antigen-specific CDR3 β s. This would have been difficult
418 to capture with methods based on pMHC-multimers, given the very low numbers of antigen-

419 specific T cells detected by these methods and the sparsity of these T cells in the overall T cell
420 repertoire. The propensity of the public ps-CDR3s to demonstrate convergent recombination
421 further exemplifies the utility of our methodology, as convergence suggests antigenic selection
422 (7, 30, 31). Through the use of single-cell sequencing technologies, we were able to elucidate
423 the matching TCR α and TCR β chains for 10 of the public ps-CDR3s, demonstrating that these
424 two methodologies in conjunction can help resolve the complete sequences that are most
425 important for the development of diagnostics and/or therapeutics.

426 In sum, by using a combination of biological and statistical enrichment of CDR3 β s from
427 antigen-activated CD4⁺ T cells, we were able to identify private and public CDR3 β s that show
428 evidence of antigenic selection. This method holds promise for application in a wide range of T
429 cell-mediated disorders, as it effectively interrogates the antigen-specific TCR repertoire in
430 unselected subjects, and potentially yields biomarkers for disease state and response to various
431 treatments.

432

433

434

435

436

437

438

439

440

441

442 **Methods**

443 **Subjects**

444 The subjects included in this study participated in a peanut oral immunotherapy trial
445 (NCT01750879) conducted at the Food Allergy Center at Massachusetts General Hospital.
446 Criteria to be screened for the study included having a previous diagnosis of peanut allergy, a
447 history of peanut-induced reactions consistent with immediate hypersensitivity, and peanut-
448 specific serum IgE levels greater than 5 kU/L (ImmunoCAP; Thermo Fisher). Subjects who met
449 these criteria underwent a double-blind placebo-controlled food challenge to confirm peanut
450 allergy. Increasing peanut protein doses were administered every 20 minutes up to a maximum
451 dose of 300 mg according to the following schedule: 3, 10, 30, 100, and 300 mg. All 27
452 individuals included in this study had an objective allergic reaction during the food challenge.

453

454 **Cell culture and sorting of peanut-activated and resting memory CD4⁺ T cells**

455 Patient blood samples were collected at baseline (before the food challenge and the start
456 of peanut oral immunotherapy), and PBMCs were isolated by means of density gradient
457 centrifugation (Ficoll-Paque Plus; GE Healthcare). Fresh PBMCs were cultured in AIM V
458 medium (Gibco) for 20 hours at a density of 5×10^6 in 1 mL medium per well in 24-well plates,
459 and were left unstimulated or cultured with 100 μ g/mL peanut protein extract (15×10^6 PBMCs
460 per variable). The peanut extract was prepared by agitating defatted peanut flour (Golden Peanut
461 and Tree Nuts) with PBS, centrifugation, and sterile-filtering. PE-conjugated anti-CD154 (clone
462 TRAP1; BD Biosciences) was added to the cultures (20 μ L/well) for the last 3 hours. After
463 harvesting, the cells were labeled with AF700-conjugated anti-CD3 (clone UCHT1), APC-Cy7-
464 conjugated anti-CD4 (RPA-T4), FITC-conjugated anti-CD45RA (HI100), PE-conjugated anti-

465 CD154 (all from BD Biosciences), AF647-conjugated anti-CD69 (FN50; BioLegend), and
466 Live/Dead Fixable Violet stain (L34955; Thermo Fisher). Live CD3⁺CD4⁺CD45RA⁻ activated
467 CD154⁺ and resting CD154⁻CD69⁻ T cells were sorted with a FACS Aria II instrument (BD
468 Biosciences). Sorted T cells were lysed in Buffer RLT Plus (Qiagen) with 1% β-mercaptoethanol
469 (Millipore-Sigma), and stored at -80°C, before total RNA and genomic DNA were isolated using
470 the AllPrep DNA/RNA Micro Kit (Qiagen).

471

472 **Expansion of Ara h 1-specific CD4⁺ T cells and sorting of pMHC-Tetramer⁺ T cells**

473 Cryopreserved PBMCs from one of the 27 subjects (patient 107) were thawed and
474 cultured in RPMI 1640 + 2 mM Glutamax (both from Gibco) + 10% human serum (Millipore-
475 Sigma) + 100 U/ml penicillin and 100 µg/ml streptomycin (Thermo Fisher) (complete RPMI)
476 with 50 µg/ml natural Ara h 1 (Indoor Biotechnologies), at a density of 6 x 10⁶ cells in 1 ml
477 medium per well in 24-well plates. Complete RPMI + 10 U/mL IL-2 (R&D Systems) was added
478 after 5 days, and cells were cultured for a total of 14 days to expand Ara h 1-specific CD4⁺ T
479 cells. After harvesting, memory CD4⁺ T cells were isolated with the EasySep human memory
480 CD4⁺ T cell enrichment kit (Stemcell Technologies), and labeled with APC-conjugated Ara h 1
481 (DRB1*03:01, AA 415-426) tetramer (32) (made in-house in James Moon's lab), at a
482 concentration of 10 nM for 1 hour at room temperature. After washing off excess tetramer, the
483 cells were labeled with BUV395-conjugated anti-CD3 (clone UCHT1; BD Biosciences), APC-
484 Cy7-conjugated anti-CD4, FITC-conjugated anti-CD45RA, and Live/Dead Fixable Blue stain
485 (L23105; Thermo Fisher), for 30 minutes at 4°C. Live CD3⁺CD4⁺CD45RA⁻ tetramer⁺ and
486 tetramer⁻ T cells were sorted with a FACS Aria Fusion instrument (BD Biosciences), and
487 genomic DNA was isolated using the AllPrep DNA/RNA Micro Kit.

488

489 **TCR β sequencing**

490 Genomic DNA was used to amplify and sequence the complementarity-determining
491 region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies). The immunoSEQ
492 approach generates an 87 basepair fragment capable of identifying the VDJ region spanning each
493 unique CDR3 β . Amplicons were sequenced using the Illumina NextSeq platform. Using a
494 baseline developed from a suite of synthetic templates, primer concentrations and computational
495 corrections were used to correct for the primer bias common to multiplex PCR reactions. Raw
496 sequence data were filtered on the basis of TCR β V, D, and J gene definitions provided by the
497 IMGT database (www.imgt.org) and binned using a modified nearest-neighbor algorithm to
498 merge closely related sequences and remove both PCR and sequencing errors.

499

500 **Selection of ps-CDR3s**

501 TCR β sequencing data from activated (CD154⁺) and resting (CD154⁻CD69⁻) memory
502 CD4⁺ T cell samples of all 27 peanut-allergic individuals were parsed using the *tcR* package
503 (version 2.2.3) in R (33). We applied a statistical method to define putatively peanut-specific
504 CDR3 β s (ps-CDR3s), i.e. sequences that are likely to be antigen-specific and not detected due to
505 bystander activation. This methodology's workflow starts with performing a G-test of
506 independence on every unique CDR3 β found in an individual's activated CD154⁺ T cell sample,
507 to determine if the proportion of a given sequence is higher in the activated CDR3 β s than the
508 resting CDR3 β s. A G-test (also known as a likelihood ratio test) can be described by the
509 formula:

510

$$G = 2 \sum_i O_i * \ln \left(\frac{O_i}{E_i} \right)$$

511 where O_i is the observed read count of a given CDR3 β in a particular population (activated or
512 resting) and E_i is the expected count based on the proportion of this CDR3 β in the entire memory
513 T cell population (pooled activated and resting CDR3 β s). With the G value for each CDR3 β , the
514 probability that the proportion of a CDR3 β in the activated compartment is derived by chance
515 from the proportion in the resting compartment can be calculated. All G-tests were calculated
516 using the *GTest* function from the R package *Desctools* (version 0.99.34) (34). Given the sizable
517 number of CDR3 β s that were analyzed from each individual's data, a false discovery rate (FDR)
518 correction was used to generate adjusted P-values (q-value) for each sequence, and those that
519 met a cutoff of $q < 0.05$ were considered significant for this study. To enhance the stringency
520 and reduce type 1 error, we also filtered out those CDR3 β s with a read count of only 1 in the
521 activated compartment ($n = 24520$, 46%) and those with a proportion in the activated
522 compartment being less than that in the resting compartment ($n = 4$, 0.008%). All sequences
523 selected after filtering were deemed putatively peanut-specific (ps-)CDR3s.

524

525 **Minimum Hamming and Levenshtein distances**

526 To determine global levels of similarity, the minimum Hamming distance (number of
527 amino acid differences among CDR3 β s of same length) and minimum Levenshtein distance
528 (minimum number of insertions/deletions/substitutions between CDR3 β s) of each ps-CDR3
529 against all other ps-CDR3s was determined using R (version 3.5.1) with the package *stringdist*
530 (version 0.9.5.1). The percentage of ps-CDR3s at each minimum Hamming or Levenshtein
531 distance was calculated. As a control, the minimum Hamming and Levenshtein distances of 100
532 equal-sized random resamplings of CDR3 β s from the total activated and resting T cell pools

533 were determined. The median percentage of sequences at each minimum Hamming and
534 Levenshtein distance for the 100 resamplings was calculated.

535

536 **Diversity measurements**

537 Diversity curves that measured Hill's diversity metric across diversity orders 0-4 were
538 created using the R package *alakazam* (version 0.3.0) with the *alphaDiversity* function (17).

539 Hill's diversity metric can be described by the following formula:

$$540 \quad D = \left(\sum_{j=1}^N w_j \sum_{i=1}^S P_{i|j}^q \right)^{\frac{1}{(1-q)}}$$

541 Where i represents a unique CDR3 β , j is the sample size, $P_{i|j}$ is the proportional abundance of
542 the i^{th} CDR3 β in the j^{th} sample, W_j is the proportional abundance of the j^{th} sample relative to the
543 entire dataset and q is a tuning parameter. q controls the influence of abundant over rare species
544 on the metric (as q increases, the abundance of dominant sequences is more heavily weighted).

545 Therefore, examining Hill's diversity metric across different values of q captures both the
546 richness and abundance of species. The fold-change of Hill's diversity metric of all pairwise
547 combinations of ps-CDR3s, total activated CDR3 β s and resting CDR3 β s was determined and the
548 differences in these distributions were compared.

549

550 **Paired single-cell TCR α/β sequencing**

551 In parallel experiments, peanut protein-activated CD154⁺ memory CD4⁺ T cells from 12
552 of the 27 subjects were processed for single-cell RNA sequencing using the Seq-Well platform
553 as previously described (35). A portion of each cDNA library was reserved for paired TCR α/β
554 enrichment. Paired TCR sequencing was performed according to Tu et al (21). Briefly,

555 following cDNA amplification, biotinylated capture probes for human TRAC and TRBC regions
556 were annealed to cDNA. Magnetic streptavidin beads were used to enrich the bound TCR
557 sequences, which were then further amplified using human V-region primers and prepared for
558 sequencing using Nextera sequencing handles. Libraries were sequenced on an Illumina MiSeq
559 using 150bp-length reads.

560 TCR sequencing reads were preprocessed according to Tu et al (21). In short, reads were
561 mapped to TCRV and TCRJ IMGT reference sequences via IgBlast, and V and J calls with
562 “strong plurality” (wherein the ratios of the most frequent V and J calls to the second most
563 frequent calls were at least 0.6) were retained. CDR3 sequences were called by identifying the
564 104-cysteine and 118-phenylalanine according to IMGT references and translating the amino
565 acid sequences in between those residues.

566

567 **Motif analysis**

568 CDR3 β amino acid sequences were trimmed to the region most likely to be in contact
569 with antigenic peptide (IMGT positions 106-117), as the stem positions of CDR3 β s are not
570 predicted to be involved with antigen binding (2). The trimmed sequences were then broken into
571 all possible continuous nmers of size 3, 4, and 5 amino acids. In addition, discontinuous motifs
572 were generated of size 4 and 5, allowing for gaps in the sequences so long as there were still 3
573 conserved residues. The proportion of each nmer in the ps-CDR3s was calculated by dividing
574 the number of reads containing that nmer by the total number of ps-CDR3 reads. To determine
575 fold-enrichment, this proportion of ps-CDR3 reads with a given nmer was divided by the
576 proportion of reads in the resting CDR3 β s with the nmer.

577

578 **Network analysis**

579 Each unique ps-CDR3 sequence was represented as a node and edges between nodes
580 were made if there was a Levenshtein distance of 1 between them or if they shared an enriched
581 motif. Levenshtein distances were determined using the R package *stringdist* (version 0.9.5.1).
582 A self-edge was created on a node for every additional nucleotide sequence that corresponded to
583 the same amino acid sequence. Network object (gml) files were created in R using the *igraph*
584 package (version 1.0.1) and network visualization was performed with Cytoscape 3.7.0, using a
585 force-directed open-CL layout. To evaluate the amount of structure present among ps-CDR3s,
586 the number of edges in ps-CDR3s was compared with the median number of edges in 100 equal-
587 sized random resamplings of resting and activated CDR3 β sequences, by creating edges between
588 the sequences of each resampling if they were within a Levenshtein distance of 1, had an
589 enriched motif, or if sequences demonstrated convergence.

590

591 **T cell subset sorts and probing for ps-CDR3 sequences**

592 Cryopreserved PBMCs from 8 of the 27 subjects (Suppl. Table 1) were thawed, and
593 memory CD4⁺ T cells were isolated with the EasySep human memory CD4⁺ T cell enrichment
594 kit. Memory T cells were labeled with APC-Cy7-conjugated anti-CD4, PerCP-Cy5.5-conjugated
595 anti-CRTH2 (clone BM16; BD Biosciences), BV605-conjugated anti-CCR4 (L291H4;
596 BioLegend), AF647-conjugated anti-CXCR5 (J252D4; BioLegend), PE-Cy7-conjugated anti-
597 PD1 (eBioJ105; eBioscience), FITC-conjugated anti-CXCR3 (G025H7; BioLegend), BUV395-
598 conjugated anti-CCR5 (2D7/CCR5; BD Biosciences), eFluor450-conjugated anti-CD161 (HP-
599 3G10; eBioscience), BV711-conjugated anti-CCR6 (11A9; BD Biosciences), and Live/Dead
600 Fixable Blue stain. Live CD4⁺ CXCR3⁺CCR5⁺ T_H1 cells, CRTH2⁺CCR4⁺ T_H2 cells,

601 CD161⁺CCR6⁺ T_H17 cells and CXCR5⁺ T_{FH} cells were sorted with a FACSAria Fusion
602 instrument. T_H2 cells were gated out first, then T_{FH} cells, then T_H1 cells, and finally T_H17 cells.
603 Sorted T cell subsets then underwent the TCR β sequencing protocol described above. These T
604 cell subset libraries were probed for the ps-CDR3 amino acid sequences from the corresponding
605 subjects. To determine the degree of overlap between the ps-CDR3s detected in each subset, a
606 Jaccard index was calculated between the unique ps-CDR3 sequences found in each pairwise
607 combination of subsets. The Jaccard index was calculated using the R package *OmicMarker*
608 (version 1.16.0) and the resulting matrix was visualized with the R package *ComplexHeatmap*
609 (version 2.0.0) (36).

610

611 **Statistics**

612 A p-value less than 0.05 was considered significant for this study. In all boxplots shown
613 in this manuscript, the lower and upper hinges correspond to the first and third quartiles (the 25th
614 and 75th percentiles). The upper whisker extends from the hinge to the largest value no further
615 than 1.5 x IQR from the hinge (where IQR is the inter-quartile range, or distance between the
616 first and third quartiles). The lower whisker extends from the hinge to the smallest value at most
617 1.5 x IQR from the hinge. Data beyond the end of the whiskers (“outlying” points) are plotted
618 individually. All comparisons made with matched pairs of values from individual subjects were
619 tested with a Wilcoxon matched-pairs signed rank test. Such comparisons include frequencies of
620 CD154⁺ T cells per million CD4⁺ T cells in cultures and differences in the ratios of diversities in
621 resting, activated and ps-CDR3 pools. Evaluation of enrichment of ps-CDR3s at minimum
622 Hamming/Levenshtein distances utilized a 2-sided Fisher’s exact test, comparing the median
623 frequencies of activated or resting CDR3 β s to the observed frequency in the ps-CDR3s. To

624 assess differences in diversity, the empirical cumulative distribution function of bootstrap delta
625 distribution was used as described by Stern et al. (37). Comparisons of public and private ps-
626 CDR3 repertoire features, such as the number of nucleotide insertions, total rearrangements and
627 node degree in the ps-CDR3 network were done with a Mann-Whitney U test. A 2-sided
628 Fisher's exact test was used to compare the proportion of public ps-CDR3s with an enriched
629 motif to private ps-CDR3s with a motif. Similarly, a 2-sided Fisher's exact test was used to
630 compare the proportion of public ps-CDR3s with an edge in the ps-CDR3 network to that of the
631 private ps-CDR3s. A z-test was used to evaluate the number of edges created within the ps-
632 CDR3 network to that of the distribution of edges created by 100 equal-sized random samplings
633 of resting or activated CDR3 β s. Associations between CD4⁺ T cell subset ps-CDR3s and clonal
634 expansion were evaluated with logistic regression using the *glm* function in R. For each subset,
635 ps-CDR3 membership was predicted with the sequences' read counts.

636

637 **Data Availability**

638 The TCR β sequencing datasets used for this project have been deposited at the National
639 Center for Biotechnology Information database of Genotypes and Phenotypes (dbGaP) under
640 accession phs001897.v1.p1.

641

642 **Code availability**

643 The source code used in this study will be available at
644 https://github.com/nealpsmith/peanut_pscdr3.

645

646 **Study approval**

647 All subjects were recruited with informed consent prior to sample collection, and the
648 study was approved by the Institutional Review Board of Partners Healthcare (protocol no.
649 2012P002153). The study was conducted according to the principles of the Declaration of
650 Helsinki.

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670 **Author contributions**

671 NPS, BR, WGS and JCL designed the study. NPS and BR performed all of the lab work
672 and generated all of the bulk TCRseq data. AAT and BM generated the single-cell TCRseq data.
673 NPS, YVV and WGS performed the data analysis. NPS and BR wrote the manuscript. JJM
674 developed the pMHC-tetramers used in this study. All authors reviewed and approved the final
675 version of the manuscript.

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693 **Acknowledgements**

694 We would like to thank our patients and their families who generously gave their time
695 and participation, as well as Lauren Tracy, Colby Rondeau, Christine Elliot, and Leah Hayden,
696 the clinical research coordinators who were instrumental in obtaining the samples used in the
697 study. We would also like to thank the staff at the MGH Department of Pathology Flow and
698 Image Cytometry Research Core who helped with the FACS. The Flow Core obtained funding
699 from the National Institutes of Health Shared Instrumentation program (grant nos.
700 1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, and 1S10RR023440-01A1).
701 Additionally, we would like to thank Alexandra-Chloé Villani for her assistance with the TCR β
702 sequencing used in the study and Andre Han for technical assistance with the tetramer
703 production. This work was supported by the NIH/NIAID (grant U19AI095261 to WGS, JJM
704 and Andrew D. Luster, and K23AI130408 to YVV) and the Food Allergy Science Initiative
705 (FASI).

706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725

726 **References**


- 727 1. Lythe G, Callard RE, Hoare RL, and Molina-Paris C. How many TCR clonotypes does a
728 body maintain? *J Theor Biol.* 2016;389:214-24.
- 729 2. Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, et al. Identifying specificity
730 groups in the T cell receptor repertoire. *Nature.* 2017;547(7661):94-8.
- 731 3. Shugay M, Bagaev DV, Zvyagin IV, Vroomans RM, Crawford JC, Dolton G, et al.
732 VDJdb: a curated database of T-cell receptor sequences with known antigen specificity.
733 *Nucleic Acids Res.* 2018;46(D1):D419-D27.
- 734 4. Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, et al.
735 Quantifiable predictive features define epitope-specific T cell receptor repertoires.
736 *Nature.* 2017;547(7661):89-93.
- 737 5. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, and Argat VP. T cell receptor
738 repertoire for a viral epitope in humans is diversified by tolerance to a background major
739 histocompatibility complex antigen. *J Exp Med.* 1995;182(6):1703-15.
- 740 6. Li H, Ye C, Ji G, and Han J. Determinants of public T cell responses. *Cell Res.*
741 2012;22(1):33-42.
- 742 7. Venturi V, Kedzierska K, Price DA, Doherty PC, Douek DC, Turner SJ, et al. Sharing of
743 T cell receptors in antigen-specific responses is driven by convergent recombination.
744 *Proc Natl Acad Sci U S A.* 2006;103(49):18691-6.
- 745 8. Sicherer SH, and Sampson HA. Food allergy: A review and update on epidemiology,
746 pathogenesis, diagnosis, prevention, and management. *J Allergy Clin Immunol.*
747 2018;141(1):41-58.
- 748 9. Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, et al. Identification of a T
749 follicular helper cell subset that drives anaphylactic IgE. *Science.* 2019;365(6456).
- 750 10. Ruiter B, Smith NP, Monian B, Tu AA, Fleming E, Virkud YV, et al. Expansion of the
751 CD4(+) effector T-cell repertoire characterizes peanut-allergic patients with heightened
752 clinical sensitivity. *J Allergy Clin Immunol.* 2020;145(1):270-82.
- 753 11. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, et al. A
754 phenotypically and functionally distinct human TH2 cell subpopulation is associated with
755 allergic disorders. *Sci Transl Med.* 2017;9(401).
- 756 12. Ryan JF, Hovde R, Glanville J, Lyu SC, Ji X, Gupta S, et al. Successful immunotherapy
757 induces previously unidentified allergen-specific CD4+ T-cell subsets. *Proc Natl Acad
758 Sci U S A.* 2016;113(9):E1286-95.
- 759 13. Wang W, Lyu SC, Ji X, Gupta S, Manohar M, Dhondalay GKR, et al. Transcriptional
760 changes in peanut-specific CD4+ T cells over the course of oral immunotherapy. *Clin
761 Immunol.* 2020;219:108568.
- 762 14. Chattopadhyay PK, Yu J, and Roederer M. Live-cell assay to detect antigen-specific
763 CD4+ T-cell responses by CD154 expression. *Nat Protoc.* 2006;1(1):1-6.
- 764 15. Renand A, Farrington M, Whalen E, Wambre E, Bajzik V, Chinthrajah S, et al.
765 Heterogeneity of Ara h Component-Specific CD4 T Cell Responses in Peanut-Allergic
766 Subjects. *Front Immunol.* 2018;9:1408.
- 767 16. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Cramer R, et al. Immune
768 responses in healthy and allergic individuals are characterized by a fine balance between
769 allergen-specific T regulatory 1 and T helper 2 cells. *J Exp Med.* 2004;199(11):1567-75.

- 770 17. Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, and Kleinstein SH.
771 Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire
772 sequencing data. *Bioinformatics*. 2015;31(20):3356-8.
- 773 18. Khosravi-Maharlooei M, Obradovic A, Misra A, Motwani K, Holzl M, Seay HR, et al.
774 Crossreactive public TCR sequences undergo positive selection in the human thymic
775 repertoire. *J Clin Invest*. 2019;129(6):2446-62.
- 776 19. Madi A, Shifrut E, Reich-Zeliger S, Gal H, Best K, Ndifon W, et al. T-cell receptor
777 repertoires share a restricted set of public and abundant CDR3 sequences that are
778 associated with self-related immunity. *Genome Res*. 2014;24(10):1603-12.
- 779 20. Venturi V, Chin HY, Asher TE, Ladell K, Scheinberg P, Bornstein E, et al. TCR beta-
780 chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV. *J Immunol*.
781 2008;181(11):7853-62.
- 782 21. Tu AA, Gierahn TM, Monian B, Morgan DM, Mehta NK, Ruiter B, et al. TCR
783 sequencing paired with massively parallel 3' RNA-seq reveals clonotypic T cell
784 signatures. *Nat Immunol*. 2019;20(12):1692-9.
- 785 22. Ritvo PG, Saadawi A, Barennes P, Quiniou V, Chaara W, El Soufi K, et al. High-
786 resolution repertoire analysis reveals a major bystander activation of Tfh and Tfr cells.
787 *Proc Natl Acad Sci U S A*. 2018;115(38):9604-9.
- 788 23. Madi A, Poran A, Shifrut E, Reich-Zeliger S, Greenstein E, Zaretsky I, et al. T cell
789 receptor repertoires of mice and humans are clustered in similarity networks around
790 conserved public CDR3 sequences. *Elife*. 2017;6.
- 791 24. James KR, Gomes T, Elmentaite R, Kumar N, Gulliver EL, King HW, et al. Distinct
792 microbial and immune niches of the human colon. *Nat Immunol*. 2020;21(3):343-53.
- 793 25. Frensch M, Arbach O, Kirchoff D, Moewes B, Worm M, Rothe M, et al. Direct access
794 to CD4+ T cells specific for defined antigens according to CD154 expression. *Nat Med*.
795 2005;11(10):1118-24.
- 796 26. Archila LD, Chow IT, McGinty JW, Renand A, Jeong D, Robinson D, et al. Ana o 1 and
797 Ana o 2 cashew allergens share cross-reactive CD4(+) T cell epitopes with other tree
798 nuts. *Clin Exp Allergy*. 2016;46(6):871-83.
- 799 27. Chiang D, Chen X, Jones SM, Wood RA, Sicherer SH, Burks AW, et al. Single-cell
800 profiling of peanut-responsive T cells in patients with peanut allergy reveals
801 heterogeneous effector TH2 subsets. *J Allergy Clin Immunol*. 2018;141(6):2107-20.
- 802 28. Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, et al.
803 Marburg virus survivor immune responses are Th1 skewed with limited neutralizing
804 antibody responses. *J Exp Med*. 2017;214(9):2563-72.
- 805 29. Weissler KA, Rasooly M, DiMaggio T, Bolan H, Cantave D, Martino D, et al.
806 Identification and analysis of peanut-specific effector T and regulatory T cells in children
807 allergic and tolerant to peanut. *J Allergy Clin Immunol*. 2018;141(5):1699-710 e7.
- 808 30. Joachims ML, Leehan KM, Lawrence C, Pelikan RC, Moore JS, Pan Z, et al. Single-cell
809 analysis of glandular T cell receptors in Sjogren's syndrome. *JCI Insight*. 2016;1(8).
- 810 31. Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, et al. High-
811 resolution analysis of the human T-cell receptor repertoire. *Nat Commun*. 2015;6:8081.
- 812 32. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, and Kwok WW. Ara h 1-
813 reactive T cells in individuals with peanut allergy. *J Allergy Clin Immunol*.
814 2011;127(5):1211-8 e3.


- 815 33. Nazarov VI, Pogorelyy MV, Komech EA, Zvyagin IV, Bolotin DA, Shugay M, et al. tcR:
816 an R package for T cell receptor repertoire advanced data analysis. *BMC Bioinformatics*.
817 2015;16:175.
- 818 34. Andri Sea. 2021.
- 819 35. Gierahn TM, Wadsworth MH, 2nd, Hughes TK, Bryson BD, Butler A, Satija R, et al.
820 Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. *Nat*
821 *Methods*. 2017;14(4):395-8.
- 822 36. Gu Z, Eils R, and Schlesner M. Complex heatmaps reveal patterns and correlations in
823 multidimensional genomic data. *Bioinformatics*. 2016;32(18):2847-9.
- 824 37. Stern JN, Yaari G, Vander Heiden JA, Church G, Donahue WF, Hintzen RQ, et al. B
825 cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
826 *Sci Transl Med*. 2014;6(248):248ra107.

827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860


861 **Figures**
 862




863
 864 **Figure 1 : Selection of putatively peanut-specific CDR3 β sequences (ps-CDR3s).** A, A
 865 general schema for the selection of ps-CDR3s (see methods). B, The frequency of CD154⁺ T
 866 cells per million CD4⁺ T cells in peanut protein-stimulated PBMC cultures is higher than in
 867 unstimulated cultures (n = 27, *** P < 0.001, Wilcoxon matched-pairs signed rank test). C, The
 868 frequency of ps-CDR3s per million CD4⁺ T cells in peanut protein-stimulated cultures (n = 27).
 869



870
 871 **Figure 2: ps-CDR3s demonstrate increased similarity and decreased diversity when**
 872 **compared to total activated and resting CDR3βs.** A-B, Minimum Hamming and Levenshtein
 873 distance of ps-CDR3s compared to 100 equal-sized random resamplings of total activated and
 874 resting CDR3βs (** P < 0.01, ps-CDR3 vs. resting and ps-CDR3 vs. activated, Fisher's exact
 875 test). C, Smoothed Hill's diversity curve at diversity orders 0-4 for 6 subjects. Diversity of ps-
 876 CDR3s was significantly lower than that of activated and resting CDR3βs at all diversity orders
 877 (P < 0.01, empirical cumulative distribution function of bootstrap delta distribution, see
 878 Methods). D, Fold-change of Hill's diversity metric of resting/ps-CDR3, activated/ps-CDR3,
 879 and resting/activated CDR3βs. Distributions represent values from 25 subjects with > 30 unique
 880 ps-CDR3s (** P < 0.01, Wilcoxon matched-pairs signed rank test).




881
 882 **Figure 3: Public ps-CDR3s are characterized by being closer to germline and exhibiting**
 883 **convergent recombination.** A, Public ps-CDR3s are closer to germline than private ps-CDR3s.
 884 Distribution of total, V-D and D-J insertions of public and private ps-CDR3s (** P < 0.01,
 885 Mann-Whitney U test). B, Public ps-CDR3s demonstrate more convergent recombination than
 886 private ps-CDR3s. Violin plots represent the number of unique nucleotide sequences responsible
 887 for each unique public and private ps-CDR3 (** P < 0.01, Mann-Whitney U test). C,
 888 Convergence of public ps-CDR3s occurs in both germline (V-gene) and non-germline (CDR3 β)
 889 regions. Logo plots represent the probability of either specific gene segments (red) or CDR3 β
 890 nucleotides (blue) to be encoding for their corresponding amino acid sequence.




891
892
893
894
895
896
897
898
899
900
901

Figure 4: ps-CDR3s contain public, dominant motifs. A-B, The ps-CDR3s contain shared, enriched motifs as compared to resting CDR3 β s. Red points represent the most dominant motifs, found to be ≥ 10 -fold enriched in ps-CDR3s as compared to resting CDR3 β s, and present in ≥ 3 unique ps-CDR3s derived from ≥ 3 subjects. C, Public ps-CDR3s are more likely to have a dominant motif than private ps-CDR3s (** $P < 0.01$, Fisher's exact test).




902
903

904 **Figure 5: Network analysis reveals that public ps-CDR3s are core sequences with more**
 905 **structure than activated and resting CDR3βs.** A, Network analysis of ps-CDR3s, where each
 906 node represents a unique ps-CDR3 amino acid sequence. Edges were created between the nodes
 907 if these were within a Levenshtein distance of 1 or if the nodes shared an enriched motif. Self-
 908 edges were created on nodes to represent additional unique nucleotide sequences encoding the
 909 same amino acid sequence (i.e. convergence). Blue nodes represent private ps-CDR3s and red
 910 nodes represent public ps-CDR3s. B, The percent of public ps-CDR3s with an edge to another
 911 ps-CDR3 (as shown in panel A) was higher than that of private ps-CDR3s (** P < 0.01, Fisher's
 912 exact test). C, The overall node degree (number of edges per node) of public ps-CDR3s was
 913 higher than that of private ps-CDR3s. Boxplots represent distribution of the node degree of all
 914 private (blue) and public (red) ps-CDR3s in the graph (** P < 0.01, Mann-Whitney U test). D,
 915 The number of total edges created among the ps-CDR3s compared to the median number of
 916 edges created among 100 equal-sized random resamplings of total activated and resting CDR3βs.
 917 Error bars represent standard deviation (** P < 0.01, z-test).





918
919
920
921
922
923
924
925
926
927

Figure 6: The frequency of ps-CDR3s is highest in the TH17 subset, but the clonal expansion of ps-CDR3s is highest in the TH2 subset. A, The percent of total read counts corresponding to a ps-CDR3 sequence was highest in the TH17 subset (n = 8). B, TH2-derived ps-CDR3s were more clonally expanded than ps-CDR3s in the other subsets. Bar represents the proportion of ps-CDR3s in a given subset based on their read count (* P < 0.01, logistic regression). C, Jaccard index showing the degree of overlap in public and private ps-CDR3s between the T cell subsets.




928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953

Supplemental figure 1. FACS gating strategy for isolating peanut-activated memory CD4⁺ T cells (CD154⁺) and resting memory CD4⁺ T cells (CD154⁻CD69⁺) from the PBMCs of peanut-allergic individuals.




954
 955 **Supplemental Figure 2: Distribution of public ps-CDR3s across the peanut-allergic**
 956 **subjects.** A, Distribution of the public ps-CDR3s over the subjects. Shown is the number of
 957 public ps-CDR3s present in a given number of individuals. B, Summary of the presence of each
 958 unique public ps-CDR3 in each subject.
 959




960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974

Supplemental Figure 3: ps-CDR3s from Ara h 1 tetramer⁺ T cells are present among ps-CDR3s derived from Ara h 1-activated T cells, and are highly expanded. A, General schema of the experimental approach. PBMCs from subject 107 were stimulated with the major peanut allergen Ara h 1 (50 µg/ml) for 20 hours, and ps-CDR3s were derived from CD154⁺ T cells. In addition, PBMCs from the same subject were cultured for 2 weeks with Ara h 1, and ps-CDR3s were derived from sorted Ara h 1 (DRB1*03:01, AA 415-426) tetramer⁺ T cells (see Methods). FMO = Fluorescence-minus-one control. B, Eleven ps-CDR3s from Ara h 1 tetramer⁺ T cells were also present in the ps-CDR3 pool from Ara h 1-activated CD154⁺ T cells. C, The 11 overlapping ps-CDR3s were more clonally expanded than the other ps-CDR3s derived from Ara h 1 tetramer⁺ T cells. Boxplots represent distributions of read counts of the corresponding ps-CDR3 sequences (** P < 0.01, Mann-Whitney U test).


A




B



C






D



975
976
977
978
979
980
981

Supplemental Figure 4: Motif analysis of ps-CDR3s. A, Schema of nmer generation with an example ps-CDR3 (see Methods). B-D, The ps-CDR3s contain shared and enriched 3-mer, 5-mer, and discontinuous 5-mer motifs as compared to resting CDR3s. Red points represent the most dominant motifs, which were ≥ 10 -fold enriched, in ≥ 3 unique ps-CDR3s derived from ≥ 3 subjects.



982
983
984

985 **Supplemental Figure 5: Sorting of T cell subsets from peanut-allergic individuals.** A, FACS
986 gating strategy for isolating bulk memory CD4⁺ Th2 (CRTH2⁺CCR4⁺), T_{FH} (CXCR5⁺), Th1
987 (CXCR3⁺CCR5⁺), and Th17 (CD161⁺CCR6⁺) cells (see Methods). FMO = Fluorescence-minus-
988 one control. B, Distribution of the total read counts in the T cell subset samples. C, Distribution
989 of unique CDR3 β sequences in the T cell subset samples.

990 **Table 1 : Demographics and serological data of the subjects included in the experiments**
 991 **described in this paper**
 992

Subject ID	Age (yr)	Gender	Race	Peanut-specific IgE (kU/L)
1	16	Male	Caucasian	66
19	16	Male	Caucasian	65
22	19	Female	Caucasian	148
24	36	Male	Caucasian	25
27	28	Male	Caucasian	7
29	28	Male	Caucasian	22
33	16	Female	Caucasian	84
69	15	Male	Caucasian	11
80	8	Female	African American	320
81	11	Female	Caucasian	246
84	22	Male	Caucasian	61
85	9	Male	Caucasian	151
89	8	Female	Caucasian	88
90	9	Male	Caucasian	159
93	11	Male	Caucasian	41
94	8	Male	Hispanic	74
95	8	Male	Caucasian	451
96	10	Female	Caucasian	39
97	36	Female	Asian	5
100	22	Female	Caucasian	396
101	8	Female	Caucasian	75
104	8	Male	Caucasian	432
105	22	Female	Caucasian	44
106	32	Female	Caucasian	5
107	22	Female	Caucasian	27
108	8	Male	Caucasian	650
111	22	Female	Caucasian	21

993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004

1005 **Table 2 : Full paired TCR α and TCR β sequences of 10 public ps-CDR3s as determined by**
 1006 **single-cell TCR sequencing.**
 1007

TCR α		TCR β	
V gene	CDR3	V gene	CDR3
TRAV41	CAVRGSNYKLTF	TRBV14	CASSQAGMNTEAFF
TRAV5	CAETFTGGGNKLTF	TRBV7-2	CASSLDSNQPQHF
TRAV8-6	CAVSDGGSARQLTF	TRBV12-4	CASSLRRAEAF
TRAV12-3	CAMSYSDGQKLLFA	TRBV28	CASRGLAGEVEQYF
TRAV41	CAAGNKLTF	TRBV6-5	CASRDRGPYEQYF
TRAV20	CAVQAGGLGKLSF	TRBV7-2	CASSLGTNNEQFF
TRAV35	CAGPQGGSEKLVF	TRBV29-1	CSARNTEAFF
TRAV21	CAVNTGNQFYF	TRBV20-1	CSARDPRPTNEKLFF
TRAV22	CAVERSNFGNEKLTF	TRBV7-9	CASSRGYEQYF
TRAV29	CAASGRSFPSTYKYIF	TRBV29-1	CSVQNTEAFF

1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024
 1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035
 1036
 1037

1038 **Table 3: Summary of all nmers generated from the ps-CDR3s.**
 1039

Nmer	3mer	4mer	5mer	Disc. 4mer	Disc. 5mer	Total
Unique	4376	15559	23473	8279	52833	104520
Enriched	3	26	38	9	72	148
% enriched	0.06	0.16	0.16	0.11	0.14	0.14

1040
 1041
 1042
 1043
 1044
 1045
 1046
 1047
 1048
 1049
 1050
 1051
 1052
 1053
 1054
 1055
 1056
 1057
 1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075

1076 **Supplemental Table 1: Subjects included in each set of experiments described in this paper.**
 1077

Subject ID	TCR β -seq CD154+/CD154-	T cell subset sorting	scTCR-seq CD154+	pMHC-Tetramer TCR β -seq
1	X			
19	X			
22	X	X		
24	X			
27	X	X		
29	X	X		
33	X	X	X	
69	X		X	
80	X			
81	X	X		
84	X		X	
85	X			
89	X			
90	X		X	
93	X		X	
94	X			
95	X		X	
96	X		X	
97	X	X	X	
100	X			
101	X			
104	X			
105	X		X	
106	X	X	X	
107	X	X	X	X
108	X			
111	X		X	

1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095

1096 Supplemental Table 2: HLA genotypes of the subjects in this study.

1097

1098

Subject ID	DPA1_alle le1	DPA1_alle le2	DPB1_alle le1	DPB1_alle le2	DQA1_all ele1	DQA1_all ele2	DQB1_all ele1	DQB1_all ele2	DRB1_alle le1	DRB1_alle le2	DRB3_alle le1	DRB3_alle le2	DRB4	DRB5
1	1:03:01	2:02:02	1:01:01	3:01:01	1:03:01	3:03:01 AM	3:01:01	6:03:01	13:01:01	4:01:01	1:01:02		1:03:01	
19	2:01:01	2:07:01	11:01:01	19:01:01	1:03:01	2:01:01	2:02:01	6:03:01	13:01:01	7:01:01	2:02:01		1:01:01	
22	1:03:01	1:03:01	4:01:01	4:01:01	1:02:01	3:01:01	3:02:01	6:02:01	15:01:01	4:02:01			1:03:01	1:01:01
24	2:01:01	2:01:02	1:01:01	17:01:01	2:01:01	5:01:01	2:01:01	2:02:01	3:01:01	7:01:01	1:01:02		1:01:01	
27	1:03:01	2:01:01	3:01:01	10:01:01	1:04:01	3:01:01	3:02:01	5:03:01	14:54:01	4:01:01	2:02:01		1:03:01	
29	1:03:01	2:01:01	4:01:01	13:FNVU	3:01:01	5:05:01	3:01:01	3:02:01	11:04:01	4:02:01	2:02:01		1:03:01	
33	1:03:01	2:01:07	4:01:01	13:FNVU	1:02:01	3:02:01	3:03:02	6:09:01	13:02:01	09:CWA	3:01:01		1:03:02	
69	1:03:01	1:03:01	2:01:02	13:FNVU	1:02:01	2:01:01	2:02:01	6:02:01	15:01:01	7:01:01			1:01:01	1:01:01
80	1:03:01	2	4:01:01	85:01:01	2:01:01	5:01:01	2:01:01	2:02:01	3:01:01	7:01:01	1:01:01		1:03:01	
81	1:03:01	1:03:01	2:01:01	4:01:01	1:02:01	3:01:01	3:02:01	6:02:01	15:01:01	4:02:01			1:03:01	1:01:01
84	1:03:01	2:01:01	4:01:01	10:01:01	1:01:02	1:02:01	5:01:01	6:09:01	1:02:01	13:02:01	3:01:01	3:01:01		
85	1:03:01	1:03:01	4:01:01	4:02:01	5:01:01	5:01:01	2:01:01	2:01:01	3:01:01	3:01:01	1:01:02	1:01:02		
89	1:03:01	2:06	4:02:01	5:01:01	1:02:01	1:02:01	6:02:01	6:02:01	15:01:01	15:01:01				1:01:01
90	1:03:01	1:03:01	4:01:01	4:01:01	5:01:01	5:05:01	2:01:01	3:01:01	3:01	11:01	1:01:02	2:02:01		
93			4:01:01	4:01:01	1:04:01	5:01:01	2:01:01	5:03:01	3:01:01	14:01:01	1:01:02	2:24		
94	1:03:01	1:03:01	2:01:02	4:01:01	1:01:01	1:02:01	5:01:01	6:02:01	1:03:01	15:01:01				1:01:01
95	1:03:01	1:03:01	4:01:01	4:01:01	1:02:01	5:05:01	3:01:01	6:02:01	15:01:01	11:01:01	2:02:01			1:01:01
96	1:03:01	2:01:02	1:01:01	2:01:02	3:03:01	5:05:01	3:01:01	3:02:01	12:JV	4:01:01	2:02:01		1:03:01	
97	1:03:01	1:03:01	2:01:02	48:01:00	3:01:01	5:03:01	3:01:01	3:02:01	13:12:01	4:03:01	2:02:01		1:03:01	
100	1:03:01	1:03:01	2:01:02	4:01:01	5:05:01	5:05:01	3:01:01	3:01:01	11:04:01	11:04:01	2:02:01	2:02:01		
101	1:03:01	1:03:01	3:01:01	4:01:01	1:02:01	1:02:01	6:02:01	6:04:01	15:01:01	13:02:01	3:01:01			1:01:01
104	1:03:01	1:03:01	4:01:01	4:01:01	1:02:01	2:01:01	3:03:02	6:02:01	15:01:01	7:01:01			01:03:01 N	1:01:01
105	1:03:01	2:01:01	2:01:02	5:01:01	3:01:01	5:01:01	2:01:01	3:02:01	3:01:01	4:02:01	1:01:02		1:03:01	
106	1:03:01	1:03:01	4:01:01	104:01:01	1:01:02	2:01:01	3:01:01	5:01:01	1:02:01	7:01:01			1:01:01	
107	1:03:01	1:03:01	4:01:01	20:01:01	3:01:01	5:01:01	2:01:01	3:02:01	3:01:01	4:04:01	1:01:02		1:03:01	
108	1:03:01	1:03:01	3:01:01	4:02:01	1:02:01	5:01:01	2:01:01	6:04:01	3:01:01	13:02:01	1:01:02	3:01:01		
111	1:03:01	1:03:01	2:01:02	4:01:01	1:03:01	5:05:01	3:01:01	6:03:01	13:01:01	13:05:01	1:01:02	2:02:01		